This inventor holds 2 USPTO granted patents. Top assignee: Icahn School of Medicine at Mount Sinai. Active years: 2017-2020.
Company Filing History:
Years Active: 2017-2020
Title: Neil Dhawan: Innovator in Cancer Research
Introduction
Neil Dhawan is a prominent inventor based in New York, NY (US). He has made significant contributions to the field of cancer research, holding 2 patents that focus on innovative therapeutic approaches.
Latest Patents
His latest patents include "KSR antagonists," which relates to antagonists of Kinase Suppressor of Ras (KSR). This invention provides pharmaceutical compositions comprising KSR inhibitors and methods of treating cancer. Another notable patent is for "Tricyclic compounds as anticancer agents." This patent discloses tricyclic chemical modulators of FOXO transcription factor proteins, which are useful in treating cancer, age-onset proteotoxicity, stress-induced depression, inflammation, and acne. The compounds are derived from phenothiazine, dibenzoazepine, and annulene, among similar genera.
Career Highlights
Neil Dhawan is currently affiliated with the Icahn School of Medicine at Mount Sinai, where he continues to advance his research in cancer therapies. His work is characterized by a commitment to developing innovative solutions that address critical health challenges.
Collaborations
Some of his notable coworkers include Michael H Ohlmeyer and Goutham Narla, who contribute to the collaborative environment that fosters innovation in their research endeavors.
Conclusion
Neil Dhawan's contributions to cancer research through his patents and collaborations highlight his role as a key innovator in the field. His work continues to pave the way for new therapeutic strategies that can significantly impact patient care.